M
Monika Warmuth-Metz
Researcher at University of Würzburg
Publications - 228
Citations - 9997
Monika Warmuth-Metz is an academic researcher from University of Würzburg. The author has contributed to research in topics: Medulloblastoma & Medicine. The author has an hindex of 53, co-authored 211 publications receiving 8613 citations. Previous affiliations of Monika Warmuth-Metz include University of Bonn & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
Stefan Rutkowski,Udo Bode,Frank Deinlein,Holger Ottensmeier,Monika Warmuth-Metz,Niels Soerensen,Norbert Graf,Angela Emser,Torsten Pietsch,Johannes E. A. Wolff,Rolf D. Kortmann,Joachim Kuehl +11 more
TL;DR: Postoperative chemotherapy alone is a promising treatment for medulloblastoma in young children without metastases in children who have complete resection, residual tumor, and macroscopic metastases.
Journal ArticleDOI
Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study
Martin Bendszus,Martin Koltzenburg,Ralph Burger,Monika Warmuth-Metz,Erich Hofmann,Laszlo Solymosi +5 more
TL;DR: After diagnostic and interventional cerebral angiography, embolic events are more frequent than the apparent neurological complication rate.
Journal ArticleDOI
Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
Rolf D. Kortmann,Joachim Kühl,Beate Timmermann,Uwe Mittler,Christian Urban,Volker Budach,Eckart Richter,Normann Willich,Michael Flentje,Frank Berthold,Slavc I,Johannes Wolff,Christoph Meisner,Otmar D. Wiestler,Nils Sörensen,Monika Warmuth-Metz,Michael Bamberg +16 more
TL;DR: Maintenance chemotherapy would seem to be more effective in low-risk medulloblastoma, especially in patients older than 6 years of age, and quality control of radiotherapy revealed correct treatment in more than 88% for dose prescription, more than 90% for coverage of target volume, and 98% for field matching.
Journal ArticleDOI
Postoperative Adjuvant Dendritic Cell ^ Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
Steven De Vleeschouwer,Steffen Fieuws,Stefan Rutkowski,Frank Van Calenbergh,Johannes van Loon,Jan Goffin,Raf Sciot,Guido Wilms,Philippe Demaerel,Monika Warmuth-Metz,Niels Soerensen,Johannes E. A. Wolff,Johannes E. A. Wolff,Sabine Wagner,Eckhart Kaempgen,Stefaan Van Gool +15 more
TL;DR: Adjuvant DC-based immunotherapy for patients with relapsed GBM is safe and can induce long-term survival and a trend to PFS improvement was shown in the faster vaccination schedule, which was observed in favor of the faster DC vaccination schedule with tumor lysate boosting.
Journal ArticleDOI
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.
Lindsey M. Hoffman,Sophie E. M. Veldhuijzen van Zanten,Niclas Colditz,Joshua J Baugh,Brooklyn Chaney,Marion Hoffmann,Marion Hoffmann,Adam Lane,Christine Fuller,Lili Miles,Cynthia Hawkins,Ute Bartels,Eric Bouffet,Stewart Goldman,Sarah Leary,Nicholas K. Foreman,Roger J. Packer,Katherine E. Warren,Alberto Broniscer,Mark W. Kieran,Jane E. Minturn,Melanie Comito,Emmett Broxson,Chie Schin Shih,Soumen Khatua,Murali Chintagumpala,Anne Sophie Carret,Nancy Yanez Escorza,Tim Hassall,David S. Ziegler,David S. Ziegler,Nicholas G. Gottardo,Hetal Dholaria,Renee Doughman,Martin Benesch,Rachid Drissi,Javad Nazarian,Nada Jabado,Nathalie Boddaert,Pascale Varlet,Géraldine Giraud,Géraldine Giraud,David Castel,Stéphanie Puget,Chris Jones,Esther Hulleman,Piergiorgio Modena,Marzia Giagnacovo,Manila Antonelli,Torsten Pietsch,Gerrit H. Gielen,David T.W. Jones,Dominik Sturm,Dominik Sturm,Stefan M. Pfister,Stefan M. Pfister,Nicolas U. Gerber,Michael A. Grotzer,Elke Pfaff,Elke Pfaff,André O. von Bueren,Darren Hargrave,Guirish A. Solanki,Filip Jadrijevic Cvrlje,Gertjan J.L. Kaspers,Gertjan J.L. Kaspers,William P. Vandertop,Jacques Grill,Simon Bailey,Veronica Biassoni,Maura Massimino,Raphael Calmon,Esther Sanchez,Brigitte Bison,Monika Warmuth-Metz,James L. Leach,Blaise V. Jones,Dannis G. van Vuurden,Christof M. Kramm,Maryam Fouladi +79 more
TL;DR: Clinical, radiologic, and molecular factors that correlate with survival in children and young adults with DIPG are reported, which are important for risk stratification in future clinical trials.